Cloprostenol is a synthetic analogue of prostaglandin F2α (PGF2α). It is a potent luteolytic agent; this means that, within hours of administration, it causes the corpus luteum to stop production of progesterone, and to reduce in size over several days. It acts as a selective agonist at the prostaglandin F receptor (FP), producing rapid uterine smooth muscle contraction, local vasoconstriction within the corpus luteum and initiation of luteal cell apoptotic pathways; these pharmacodynamic effects drive the functional and structural luteolysis that underlies its use in reproductive management. The compound is most commonly supplied as a water-soluble salt for parenteral administration in veterinary formulations, is rapidly metabolized by pulmonary and hepatic enzyme systems, and has limited oral bioavailability. Standard quality control for the active substance employs reversed-phase HPLC for assay and related-substance profiling, validated dissolution and sterility testing for finished injectables, and stability testing over intended shelf life under ICH-aligned conditions.
Parent: Cloprostenol
Typical API specifications set assay by HPLC at 98.0 to 102.0 percent of labeled amount, with related substances controlled to limit total impurities to no more than 1.0 percent and any individual specified impurity to no more than 0.5 percent; unspecified impurities are commonly held below 0.10 percent. Known related compounds and degradants to monitor include the 15-keto metabolite, 15-hydroxy epimers (including 15R/15S isomers), epimerization at the C9 position, chlorine positional isomers and the enantiomeric form often referred to as D-cloprostenol; typical individual acceptance criteria for these related compounds are in the 0.1 to 0.5 percent range depending on identity and toxicological qualification, while the combined level of structurally related substances is usually limited to 1.0 percent. Residual solvents and volatile impurities are controlled per ICH Q3C limits applicable to the solvent class used in manufacture, elemental impurities are limited in accordance with ICH Q3D (for example cadmium, lead and mercury at low ppm levels as appropriate), and microbial/sterility and endotoxin testing are applied for finished sterile parenteral products.
Cloprostenol is used primarily in veterinary medicine to induce luteolysis and control reproductive cycles; common indications include synchronization of estrus, induction of parturition or abortion in livestock where indicated, treatment of luteal-related reproductive disorders and assistance in herd reproductive management programs.
Cloprostenol is a synthetic analogue of prostaglandin F2α (PGF2α); it is not identical to the endogenous molecule but mimics PGF2α activity by agonism at the FP receptor.
D-cloprostenol, denoting the enantiomeric form, acts as an FP receptor agonist similar to the L-enantiomer; receptor activation causes intracellular calcium mobilization and signalling that leads to uterine smooth muscle contraction, luteal vascular changes and initiation of luteal cell regression, producing rapid decline in progesterone levels and structural luteolysis.
Cost varies by formulation, concentration, supplier, purchase volume and region; retail veterinary injectable products typically range from a few dollars to several tens of dollars per vial or dose, while bulk API prices depend on order size and purity and can range widely from hundreds to a few thousand dollars per kilogram.
